Frontiers in Neurology (Jul 2017)

Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta

  • Kathleen Ingenhoven,
  • Daniel Kramer,
  • Poul Erik Jensen,
  • Christina Hermanrud,
  • Malin Ryner,
  • Florian Deisenhammer,
  • Marc Pallardy,
  • Til Menge,
  • Hans-Peter Hartung,
  • Bernd C. Kieseier,
  • Elisa Bertotti,
  • Paul Creeke,
  • Anna Fogdell-Hahn,
  • Clemens Warnke,
  • Clemens Warnke

DOI
https://doi.org/10.3389/fneur.2017.00305
Journal volume & issue
Vol. 8

Abstract

Read online

ObjectiveTo develop and validate a method for the detection of binding anti-drug antibodies (ADAs) against interferon beta (IFN-β) in human serum as part of a European initiative (ABIRISK) aimed at the prediction and analysis of clinical relevance of anti-biopharmaceutical immunization to minimize the risk.MethodA two-tiered bridging enzyme-linked immunosorbent assay (ELISA) format was selected and validated according to current recommendations. Screening assay: ADA in serum samples form complexes with immobilized IFN-β and biotinylated IFN-β, which are then detected using HRP labeled Streptavidin and TMB substrate. Confirmation assay: Screen “putative positive” samples are tested in the presence of excess drug (preincubation of sera with 0.3 µg/mL of soluble IFN-β) and percentage of inhibition is calculated.ResultsThe assay is precise, and the sensitivity of the assay was confirmed to be 26 ng/mL using commercially available polyclonal rabbit antihuman IFN-β in human sera as the positive control.ConclusionAn ultrasensitive ELISA for IFN-β-binding ADA testing has been validated. This will form the basis to assess anti-biopharmaceutical immunization toward IFN-β with regards to its clinical relevance and may allow for the development of predictive tools, key aims within the ABIRISK consortium.

Keywords